Does DOSTARLIMAB Cause Immune-mediated enterocolitis? 9 Reports in FDA Database
Boost Your Natural Energy & Metabolism
Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.
According to the FDA Adverse Event Reporting System (FAERS), 9 reports of Immune-mediated enterocolitis have been filed in association with DOSTARLIMAB (Jemperli). This represents 1.0% of all adverse event reports for DOSTARLIMAB.
9
Reports of Immune-mediated enterocolitis with DOSTARLIMAB
1.0%
of all DOSTARLIMAB reports
0
Deaths
5
Hospitalizations
How Dangerous Is Immune-mediated enterocolitis From DOSTARLIMAB?
Of the 9 reports, 5 (55.6%) required hospitalization.
Is Immune-mediated enterocolitis Listed in the Official Label?
This adverse event is not currently listed in the official FDA drug label for DOSTARLIMAB. However, 9 reports have been filed with the FAERS database.
What Other Side Effects Does DOSTARLIMAB Cause?
Malignant neoplasm progression (111)
Thrombocytopenia (42)
Fatigue (38)
Anaemia (36)
Death (31)
Arthralgia (30)
Diarrhoea (29)
Rash (29)
Condition aggravated (27)
Dyspnoea (26)
What Other Drugs Cause Immune-mediated enterocolitis?
NIVOLUMAB (1,289)
IPILIMUMAB (988)
PEMBROLIZUMAB (858)
CARBOPLATIN (307)
PACLITAXEL (188)
DURVALUMAB (165)
ATEZOLIZUMAB (156)
LENVATINIB (143)
PEMETREXED (129)
BEVACIZUMAB (92)
Which DOSTARLIMAB Alternatives Have Lower Immune-mediated enterocolitis Risk?
DOSTARLIMAB vs DOSTARLIMAB-GXLY
DOSTARLIMAB vs DOTATATE GALLIUM GA-68
DOSTARLIMAB vs DOTHIEPIN
DOSTARLIMAB vs DOXAZOSIN
DOSTARLIMAB vs DOXAZOSIN\DOXAZOSIN